The cellular origins of type I and type II interferons released into the circulation of mice with delayed hypersensitivity were investigated. We determined the effect of treatment with various immunosuppressive agents, including cyclophosphamide, cycloheximide, antithymocyte serum, and whole-body X-irradiation, on the release of interferons after intravenous injection of specific (old tuberculin) or nonspecific (lipopolysaccharide) stimuli. The results suggest that (i) a heterogeneous population of lymphocytes (T and B cells) produces type II interferon, (ii) type I interferon is produced by a different cell population, and (iii) type II interferon is produced de novo after challenge with old tuberculin of mice sensitized with Mycobacterium bovis BCG.
The cellular origins of type I and type II interferons released into the circulation of mice with delayed hypersensitivity were investigated. We determined the effect of treatment with various immunosuppressive agents, including cyclophosphamide, cycloheximide, antithymocyte serum, and whole-body X-irradiation, on the release of interferons after intravenous injection of specific (old tuberculin) or nonspecific (lipopolysaccharide) stimuli. The results suggest that (i) a heterogeneous population of lymphocytes (T and B cells) produces type II interferon, (ii) type I interferon is produced by a different cell population, and (iii) type II interferon is produced de novo after challenge with old tuberculin of mice sensitized with Mycobacterium bovis BCG.
Type II interferon is released into the circulation after intravenous injection of old tuberculin (OT) into mice infected with Mycobacterium bovis BCG (16, 21) . The interferon activity is detected in the serum concomitantly with migration inhibitory factor (serum MIF) activity (16, 21) . The type II interferon and serum MIF share similar physicochemical and biological properties, such as lability at pH 2, stability at 56°C for 1 h, and species specificity (21) . Type II interferon has different physicochemical properties from type, I interferon, which is produced by sensitized mice challenged with lipopolysaccharide from Salmonella typhimurium LT2. Type I interferon is pH 2 stable and heat sensitive and inhibits virus replication in guinea pig kidney cells (21) . In addition, rabbit antibodies against type I mouse interferon fail to neutralize the antiviral activity of type II interferon. Later studies showed that type II interferon and serum MIF can also be produced by mice sensitized with cell walls of M. bovis BCG in oil droplets and challenged with OT (14) .
The cellular origin of interferon is of interest since this protein has been shown to have an immunoregulatory role (9) . The cells that produce interferon may therefore be involved in regulation of other cells, using interferon as a mediator (9) . The results of this study suggest that (i) both bone marrow-derived and thymusderived lymphocytes cooperate in the production of type II interferon, (ii) types I and II interferon are synthesized by different cells, and (iii) the release of type II interferon is inhibited by pretreatment of mice with cycloheximide, whereas the release of type I is enhanced by protein synthesis inhibition.
MATERIALS Antigens and mitogens. BCG cell walls were obtained through the courtesy of E. Ribi, Rocky Mountain Laboratory, National Institute of Allergy and Infectious Diseases, Hamilton, Mont. The inoculum was prepared by placing 24.75 mg of cell walls in a 50-ml tissue grinder with a Teflon pestle and adding 0.12 mi of light mineral oil (Drakeol 6/VR, Pennsylvania Refining Co., Butler). The mixture was ground to a paste, 16 .7 ml of 0.85% NaCl containing 0.2% Tween 80 was added, and grinding continued until a well-dispersed emulsion was obtained (21) . OT was obtained from Jensen-Salsbery Laboratories, Kansas City, Mo., or from Haver-Lockhart Laboratories, Shawnee, Kan. Lipopolysaccharide (LPS) from S. typhimurium LT2 was obtained through the courtesy of G. Keleti, University of Pittsburgh, Pittsburgh, Pa. The LPS was extracted and purified by the method of Westphal and Jann (19 Antisera and immunosuppressive drugs. Antithymocyte serum was prepared by a modification of the method of Levey and Medawar (10) . The sera were assayed by an adaptation of the method of Gallily and Gornostansky (7) . Portions of antithymocyte sera (25 ml) were adsorbed with 1 Swiss-Webster mice, sensitized intravenously with 300 ,ug of BCG cell walls, received 50 mg of cyclophosphamide per kg intravenously. Three and one-half weeks later, these mice were treated with cyclophosphamide for 4 days. After this regimen the lymph nodes of the mice were reduced in size and depleted of lymphocytes in the cortical areas. The total leukocyte counts of sensitized mice not given cyclophosphamide ranged from 5,300 to 6,900 cells per mm3.
Cyclophosphamide-treated mice, challenged intravenously with 50 mg of OT 24 h after the final injection of cyclophosphamide, showed a marked reduction in the titers of circulating type II interferon. The interferon response of treated mice challenged with 1 ,ug of LPS was not affected ( Table 2) .
Effect of cycloheximide on the production of type I and type H interferons. Protein synthesis is inhibited in mice 1 h after intraperitoneal injection of 288 mg of cycloheximide per kg (22) . Mice sensitized intravenously with 300 ,ug of BCG cell walls were inoculated intraperitoneally 4 weeks later with 7 mg (288 mg/kg) of cycloheximide. One hour later, the mice were challenged intravenously with either 50 mg of OT or 1 Ag of LPS. Mice challenged with OT were bled 3.5 or 7 h after challenge; mice challenged with LPS were bled 2 or 4 h after challenge.
The sera of cycloheximide-treated mice sensitized with BCG cell walls had significantly reduced quantities of interferon 3.5 and 7 h after intravenous challenge with OT compared with those of sensitized mice not given cycloheximide (Table 3 ). However, since the interferon activity was not detectable after heating the sera at 560C for 1 h, the activity was considered to be type I interferon. This residual interferon activity was similar to the titers observed in control mice given cycloheximide alone and represents interferon production induced by this antibiotic (22) . The data in Table 3 indicate type II interferon is probably synthesized de novo after challenge with OT.
In the case of LPS, when sensitized mice were pretreated with cycloheximide, the pattern of interferon induction by LPS was shifted. There was a delayed appearance of interferon, and peak titers were seen in sera from the 7-h bleeding (Table 4 ). This delayed enhancement in cycloheximide-treated mice is typical for an endotoxin-type interferon response (22) . As expected, the inhibitor produced by injection of LPS was heat labile and therefore type I interferon.
Effect of whole-body X-irradiation on the production oftype I and type H interferons. Since whole-body X-irradiation at appropriate doses may inhibit delayed hypersensitivity, the effect of such irradiation on production of type I and type II interferons in mice was investigated.
Mice were sensitized intravenously with 300 ,ug of BCG cell walls and 4 weeks later were given doses of whole-body X-irradiation ranging from 50 to 1,000 rads. The mice were challenged intravenously with 50 mg of OT or 1 ,ug of LPS 24 h after X-irradiation.
Production of type II interferon was inhibited after whole-body X-irradiation ( with OT produced interferon that was heat labile and therefore appeared to be type I interferon (Table 5) . Whole-body X-irradiation had little or no effect on the titers of type I interferon produced after challenge of sensitized mice with LPS (Table 6). Increased amounts of X-irradiation up to lethal doses of 1,000 rads did not have an apparent effect on type I interferon production. The interferon produced in these experiments was determined to be type I on the basis of its sensitivity to heating at 56°C for 1 h ( Table 6 ).
Recovery of the ability to produce type II interferon by mice after lethal X-irradiation and reconstitution with lymphoid cells. C3H mice were exposed to 900 rads of Xirradiation and on the same day were reconstituted intravenously with 5 x 106 to 1 x 107 bone marrow cells obtained from femurs and tibias of normal C3H donor mice. Four days later, reconstituted mice and normal C3H mice were sensitized intravenously with 300,g of BCG cell walls; then, 2 to 3 weeks later, all mice were challenged intravenously with 50 mg of OT. (Table 7) .
Sensitized X-irradiated mice reconstituted with 5 x 106 to 1 x 107 bone marrow cells and similar numbers of thymus cells produced type II interferon after OT challenge ( Table 7) . The type II interferon titers produced by these irradiated mice were equivalent to the titers of type II interferon in sensitized non-irradiated mice.
It is possible that a portion of the activity lost after heat treatment of type II interferon from the reconstituted mice represented type I interferon activity, but further characterizations were not carried out.
In another experiment, other groups of mice were reconstituted intravenously with 107 bone marrow cells on the day of irradiation. Four days later, both reconstituted and normal (control) C3H mice were sensitized with 300 ug of BCG cell walls. The X-irradiated mice, reconstituted with bone marrow cells, sensitized, and then given thymus cells 10 days after sensitization, produced serum type II interferon after OT challenge (Table 8) . Thus, a 10-day delay (after sensitization) in reconstitution with thymus cells did not result in reduction of type II interferon titers. However, X-irradiated and bone marrow-reconstituted mice that received thymus cells 20 days after sensitization did not produce type II interferon after OT challenge (Table 8) . Therefore, the mice needed interaction with thymus cells for several days before OT challenge in order to produce interferon.
DISCUSSION
Thymus-derived (T) lymphocytes were originally thought to be solely responsible for in vitro production of lymphokines, i.e., serum MIF, chemotactic factor, etc. (22) . Such lymphokines were believed to be involved in the control of cell-mediated immune responses in vivo, including immunity to intracellular pathogenic microorganisms and the delayed-hypersensitivity skin and footpad reactions.
Administration of antithymocyte serum or whole-body, high-dose X-irradiation has been shown to inhibit T-cell function (2, 10, 12, 15) . In the present study, treatment of sensitized mice with antithymocyte serum or X-irradiation both inhibited the release of type II interferon into the circulation. When sensitized mice were subjected to whole-body X-irradiation 24 h before challenge with OT, titers of type II interferon decreased with low-dose irradiation, but did not reach minimal levels until after exposure of the mice to 200 or more rads of X-irradiation. The basis for the release of type I interferon in mice that received 400 to 1,000 rads of X-irradiation is not clear (Table 5 ). It is possible that high doses of X-irradiation may be lethal to cells and cause a release of type I interferon analogous to the release that occurs after administration of high doses of cycloheximide (Table  5 ) (22). Recent reports have challenged the concept that only T cells are involved in lymphokine production. The production of MIF by guinea pig B cells in vitro has been reported (20) . Complement-reactive B lymphocytes from nonimmune animals produced MIF in response to stimulation with purified protein derivative of tuberculin, suggesting that the derivative was having a mitogenic effect (20) . MIF production by purified populations of sensitized human B lymphocytes in response to specific antigenic stimulation with purified protein derivative, streptokinase-streptodornase, or Candida antigen has also been reported (13) .
Cyclophosphamide is an immunosuppressive drug that depletes the lymphoid tissue of rapidly dividing cells, including B lymphocytes (17) . Mice treated with cyclophosphamide showed depletion of lymph follicles and corticomedullary areas of lymph nodes; areas primarily affected were thymus-independent areas that contained B lymphocytes responsible for antibody production. Thus, treatment with cyclophosphamide 72 h before sensitization is a method for depleting mice of B cells while leaving the Tcell population relatively intact. Since sensitized mice treated with cyclophosphamide showed significantly reduced titers of type II interferon after challenge with OT, it is strongly suggested that B cells are involved in the production of type II interferon.
Further evidence of the possible cooperation between B and T cells in the production of type II interferon was obtained when mice were lethally irradiated, reconstituted with bone marrow cells, sensitized with BCG cell walls, and then given thymus cells 10 days after sensitization. When such reconstituted mice were challenged with OT 21 days after sensitization, they produced high levels of type II interferon in their circulation. However, if the sensitized mice received thymic cells 20 (5); and (iv) suppressor B cells may regulate production of delayed hypersensitivity (11) . T cell-B cell cooperation, therefore, may play a major role in humoral immune reactions and now appears to play a role in cell-mediated immune reactions.
Results of a concurrent study also indicate that both B and T cells are involved in production in vivo of serum-MIF detected in the sera of mice sensitized with M. bovis BCG and challenged with OT (S. B. Salvin, G. Sonnenfeld, and J. Nishio, submitted for publication). The serum MIF activity is always found concomitantly with type II interferon activity. The production of MIF is affected by such immunosuppressants as X-irradiation and cyclophosphamide to the same extent as is production of type II interferon. Type II interferon and serum MIF seem to be closely related substances and are produced by the same or closely related cells.
Several experiments were carried out to determine the role of T lymphocytes and B lymphocytes in production of LPS-induced type I interferon in mice sensitized to BCG cell walls. The effect of immunosuppressive agents on type I interferon production has been shown to be inducer dependent. X-irradiation has enhanced, suppressed, or not affected type I interferon production, depending on the agent used to induce the interferon (3). Treatment of mice with antilymphocyte serum also had effects on interferon production that were inducer dependent (4) . The production of LPS-induced type I interferon was not affected by administration of ATS or cyclophosphamide. High-and low-dosage X-irradiation also did not affect production of LPS-induced type I interferon.
Although T and B cells both appear to be involved in production of type II interferon, it must be remembered that the agents used in this study are not completely specific for T or B lymphocytes and can affect other cells. Therefore, cells other than T and B cells may also be involved in type II interferon production. Definitive proof of the cell populations responsible for type II interferon production will only be obtained when antigen-specific type II interferon can be produced in vitro.
